Price Negotiation And The GLP1 Class: Trulicity Lucky To Be A BLA
The inaugural class of drugs subject to the new US Medicare price negotiation process includes four antidiabetics. But none are from the biggest and fastest growing class – thanks to few technicalities in how the law works.
You may also be interested in...
Some drugs recorded significant increases in Medicare gross spending between the periods covered by publicly available data and what CMS had access to internally, which contributed to their unexpected presence on the list.
Neither product counts as an ‘extended monopoly’ drug under the Inflation Reduction Act, meaning biosimilar entry cannot prevent Medicare from negotiating its price.
The drug maker is looking ahead to potentially big approvals of donanemab for Alzheimer’s disease and Mounjaro for obesity by the end of the year.